[
    [
        {
            "time": "2023-03-01",
            "original_text": "康泰生物3月1日大宗交易成交2082.50万元",
            "features": {
                "keywords": [
                    "康泰生物",
                    "大宗交易",
                    "成交金额"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物3月1日大宗交易成交2082.50万元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-01",
            "original_text": "康泰生物今日大宗交易成交17万股，成交价122.5元折价21.07%",
            "features": {
                "keywords": [
                    "康泰生物",
                    "大宗交易",
                    "折价"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物今日大宗交易成交17万股，成交价122.5元折价21.07%",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业报告：医药板块大幅调整之后的布局思路",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业报告",
                    "调整",
                    "布局思路"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业报告：医药板块大幅调整之后的布局思路",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "东吴证券--医药生物行业：新冠疫苗逐步获批，巨大期权有望加速兑现【行业研究】",
            "features": {
                "keywords": [
                    "东吴证券",
                    "医药生物",
                    "新冠疫苗",
                    "获批",
                    "期权兑现"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "东吴证券--医药生物行业：新冠疫苗逐步获批，巨大期权有望加速兑现【行业研究】",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]